Search

Your search keyword '"BRANDIMARTE G"' showing total 467 results
Start Over Author "BRANDIMARTE G"
467 results on '"BRANDIMARTE G"'

111. SUPPLEMENTATION WITH THE PROBIOTIC VSL#3 IN PATIENTS WITH MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY

Author

Tursi, A., primary, Papa, A., additional, Brandimarte, G., additional, Giglio, A., additional, Elisei, W., additional, Giorgetti, G.M., additional, Forti, G., additional, Morini, S., additional, Hassan, C., additional, Pistoia, M.A., additional, Modeo, M.E., additional, Rodinò, S., additional, Di Giulio, E., additional, Luzza, F., additional, Di Rosa, S., additional, Annese, V., additional, Danese, S., additional, and Gasbarrini, A., additional

Published
2009
Full Text
View/download PDF

118. PA.168 MUCOSAL HEALING IN ULCERATIVE COLITIS PATIENTS IN LONG-TERM TREATMENT WITH INFLIXIMAB

Author

Papa, A., primary, De Vitis, I., additional, Guglielmo, S., additional, Tursi, A., additional, Brandimarte, G., additional, Elisei, W., additional, Roberto, I., additional, Ennas, S., additional, Mocci, G., additional, Bonizzi, M., additional, Felice, C., additional, Andrisani, G., additional, Guidi, L., additional, Gasbarrini, A., additional, and Fedeli, G., additional

Published
2008
Full Text
View/download PDF

120. Mechanical twins in 304 stainless steel after small-charge explosions

Author

Firrao, D., primary, Matteis, P., additional, Scavino, G., additional, Ubertalli, G., additional, Ienco, M.G., additional, Pellati, G., additional, Piccardo, P., additional, Pinasco, M.R., additional, Stagno, E., additional, Montanari, R., additional, Tata, M.E., additional, Brandimarte, G., additional, and Petralia, S., additional

Published
2006
Full Text
View/download PDF

130. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study.

Author

TURSI, A., DI MARIO, F., BRANDIMARTE, G., ELISEI, W., PICCHIO, M., LOPERFIDO, S., DAL BO'', N., FERRARA, F., MARCELLO, R., SALVAT, H. HERAS, and SCARPIGNATO, C.

Abstract

BACKGROUND: Mesalazine seems to be effective in preventing recurrence of acute uncomplicated diverticulitis (AUD), but the optimal mesalazine scheme to achieve these results is still debated. AIM: To assess the effectiveness of two different mesalazine-based treatments in preventing recurrence of AUD and the occurrence of other complications of diverticular disease (DD) during a long-term follow-up. PATIENTS AND METHODS: We reviewed 311 patients suffer from recent episode of AUD and undergoing to mesalazine treatment: 207 (group A, 105 males, median age 63 years, range 47-74 years) were treated with mesalazine 1.6 g for 10 days each month, whilst 104 (group B, 55 males, median age 65 years, range 50-72 years) were treated with mesalazine 1.6 g every day. Patients were followed-up every 6 months (median 7.5 months, range 5-13 months). RESULTS: Patients were followed-up for a mean time of 3 years (range 12-72 months). Overall, occurrence of complication recurred more frequently in group A than in group B (p = 0.030, log-rank test). Acute diverticulitis recurred in 17 (8.2%) patients in group A and in 3 (2.9%) in group B; diverticular bleeding occurred in 4 (1.9%) patients in group A and in 1 (0.96%) patient in group B; surgery was required in 3 (1.4%) patients in group A and in no (0%) patient in group B. CONCLUSIONS: This is the first study showing that long-term mesalazine treatment is significantly better that intermittent mesalazine treatment in preventing occurrence of DD complications after an attack of acute diverticulitis. [ABSTRACT FROM AUTHOR]

Published
2013

131. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.

Author

TURSI, A., ELISEI, W., GIORGETTI, G. M., INCHINGOLO, C. D., NENNA, R., PICCHIO, M., MAIORANO, M., PENNA, A., LECCA, P. G., and BRANDIMARTE, G.

Abstract

BACKGROUND: Colonic diverticulitis shows a high recurrence rate. AIMS: To assess the efficacy of three different therapeutic strategies in preventing diverticulitis recurrence. MATERIALS AND METHODS: One hundred thirty patients suffering from Acute Uncomplicated Diverticulitis (AUD) (81 males, 49 females, mean age 64.71 years, range 40-85) were prospectively assessed. After obtaining remission, considered present when both endoscopic and histological damage were absent, the patients were treated with mesalazine 1.6 g/day (59 patients, group A), or rifaximin 800 mg/day for 7 days every month (52 patients, group B). Clinical, endoscopic and histological follow-up was performed after 6, 12 and thereafter every 12 months after diagnosis of AUD. RESULTS: Seven patients were excluded from final evaluation because they were lost to follow-up. Fifty-five group A patients and 49 group B patients patients were available for the final assessment at the end of a 24-month follow-up. Sustained remission was significantly higher in group A with respect to group B. CONCLUSIONS: Patients taking mesalazine have lower risk of diverticulitis recurrence than patients taking rifaximin because of the lower prevalence of persisting endoscopic and histological inflammation. [ABSTRACT FROM AUTHOR]

Published
2013

133. Prevalence of celiac disease and symptoms in relatives of patients with celiac disease.

Author

TURSI, A., ELISEI, W., GIORGETTI, G. M., GASPARDONE, A., LECCA, P. G., DI CESARE, L., and BRANDIMARTE, G.

Abstract

Background and Objectives: We determined the prevalence and clinical features of celiac disease (CD) in family-members (FMs) of a population-based cohort of index cases. Materials and Methods: We recruited 108 CD index cases: mean age at diagnosis, 23.0 years (range, 1.5-45.2 years); 81 (75%) female. Three-hundred twelve (mean age, 41.6 years; 219 [70%] female) of FMs were analyzed. 153 (49%) were parents, 24 (7.7%) were children, 69 (22.2%) were siblings, 66 (21.1%) were second degree FMs. Results: CD was diagnosed in 63 subjects (20.1%, 21 males and 42 females, mean age 34.24 years, range 2-81 years). Classic, subclinical, and silent forms of CD were recognized in 18 [28.6% (6 siblings, 6 parents, 3 child, 3 second-degree FMs], in 27 [45.8% (9 siblings, 3 parent, 15 second-degree FMs], and in 18 [28.6% (6 siblings, 6 parents, 6 second-degree FMs) cases, respectively. Most of patients suffering from "classical" (18/63 patients, 28.7%) and "subclinical" (27/63 patients, 42.9%) form of CD were older than patients suffering from "silent " CD (18/63 patients, 28.7%) (p=0.01). Most of patients suffering from subclinical disease showed autoimmune diseases (Hashimoto's thyroiditis, and psoriasis), and other atypical symptoms, as gastroesophageal reflux disease (GERD), were also recorded. Conclusions: We found an high-prevalence of CD between CD FMs, and most of them were oly-goor asymptomatic. [ABSTRACT FROM AUTHOR]

Published
2010

134. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.

Author

TURSI, A., ELISEI, W., BRANDIMARTE, G., GIORGETTI, G., PENNA, A., and CASTRIGNANO, V.

Abstract

Background and Objectives: Our aim was to assess the efficacy and safety of infliximab (IFX) in clinical practice in three Primary Care, Hospital Centers. Material and Methods: From September 2004 to December 2008 62 patients (28 males, 34 females, mean age 30.25 years, range 15-55 years), affected by ulcerative colitis (UC) (23 pts) or by Crohn's disease (CD) (39 patients) were treated. Clinical efficacy, safety, mucosal healing and quality of life were assessed both in UC and CD. Results: A total of 746 infusions were performed. IFX was administered for a mean of 26 months (range 8-44 months). 33/39 (84.61%) pts with CD were in remission under treatment with IFX for a mean time of 19 months (range 12-44 months). Mean Crohn Disease Activity Index (CDAI) score decreased from 295 (range 258- 346) to 136 (range 98-136) (p<0.005). Inflammatory Bowel Disease Quality of Life (IBDQL) improved from 48 (at entry) to 198 (at the end of the study) (p<0.005). 20/23 (86.95%) patients with UC were in remission under treatment with IFX for a mean of 18 months (range 8-34 months). Mean Disease Activity Index (DAI) decreased from 11 (range 9-12) to < 3 (range 2-3) (p<0.05). Mean Mayo Subscore for Endoscopy decreased from 3 to <1 (range 0-1). IBDQL improved from 56 (at entry) to 194 (at the end of the study) (p<0.005). Only 5 patients (8.06%) experienced side-effects. Conclusions: Long-term outpatients treatment with IFX seems to be safe and effective in managing patients affected by IBD in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2010

136. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant: Results of an open, uncontrolled multicenter study

Author

Colecchia, A., Vestito, A., La Rocca, A., FRANCESCA PASQUI, Nikiforaki, A., DAVIDE FESTI, Abruzzo, F., Almureden, N., Angiolucci, A., Arrigoni, A., Balzano, A., Brandimarte, G., Buono, M., Calcamuggi, G., Cammarota, G., Gabriele campana, Cotticeli, G., Cuomo, R., D Amore, F., Felici, I., Anna, A., Di Bona, A., Di Cesare, D., Di Napoli, A., Sughera, L., Febbraio, I., Ferrini, G., Fornaciari, G., Gallo, S., Glielmo, G., Iafrancesco, G., La Barbera, M., Lavanda, R., Manca, A., Matarazzo, F., Mazzei, C., Monastra, S., Montalto, M., Morace, F., Murgia, R., Nico Pagano, Pio, A., Panarese, A., Paraocchi, D., Peccetti, A., Perasso, A., Perego, M., Piscopo, R., Rizzi, S., Romano, M., Rosati, S., Santoro, G., Surrenti, E., Villa, E., Colecchia, A., Vestito, A., La Rocca, A., Pasqui, F., Nikiforaki, A., Festi, D., Abruzzo, F., Almureden, N., Angiolucci, A., Arrigoni, A., Balzano, A., Brandimarte, G., Buono, M., Calcamuggi, G., Cammarota, G., Campana, G., Cotticeli, G., Cuomo, R., D'Amore, F., De Felici, I., Dell'Anna, A., Di Bona, A., Di Cesare, D., Di Napoli, A., Sughera, L., Febbraio, I., Ferrini, G., Fornaciari, G., Gallo, S., Glielmo, G., Iafrancesco, G., La Barbera, M., Lavanda, R., Manca, A., Matarazzo, F., Mazzei, C., Monastra, S., Montalto, M., Morace, F., Murgia, R., Pagano, N., Pio, A., Panarese, A., Paraocchi, D., Peccetti, A., Perasso, A., Perego, M., Piscopo, R., Rizzi, S., Romano, M., Rosati, S., Santoro, G., Surrenti, E., Villa, E., Colecchia, A, Vestito, A, La Rocca, A, Pasqui, F, Nikiforaki, A, Festi, D, Almureden, N, Angiolucci, A, Arrigoni, A, Balzano, A, Brandimarte, G, Buono, M, Calcamuggi, G, Cammarota, G, Campana, G, Cotticeli, G, Cuomo, Rosario, and others of Symbiotic Study, Group

Subjects
Male, Time Factors, Endocrinology, Diabetes and Metabolism, Oligosaccharides, Prebiotic, Probiotic, Irritable Bowel Syndrome, Endocrinology, Surveys and Questionnaires, Nutrition and Dietetic, Internal Medicine, Humans, Intestinal microflora, Symbiosis, Aged, Aged, 80 and over, Nutrition and Dietetics, Probiotics, Gastroenterology, Abdominal Pain, Intestines, Diabetes and Metabolism, Treatment Outcome, Prebiotics, Data Interpretation, Statistical, Female, Bifidobacterium, Constipation
Abstract

Aim. Irritable bowel syndrome (IBS) is frequently associated with an imbalance in intestinal bacteria. To date, few studies have evaluated the efficacy and safety of probiotic administration in patients with constipation-variant IBS. A new agent recently available in clinical practice is a symbiotic consisting of a probiotic, Bifidobacterium longum W11, and the short chain oligosaccharide prebiotic Fos Actilight. The aim of this study was to evaluate the efficacy and safety of this symbiotic in patients with constipation-variant IBS. Methods. A total of 636 patients (250 men, 386 women) diagnosed with constipation-type IBS according to the Roma II criteria were enrolled in 43 centers and received the symbiotic at a dose of 3 g/die for at least 36 days. A validated questionnaire investigating symptoms and stool frequency was administered before and after treatment. Results. Based on patient responses to visual scale items, frequency increased significantly after treatment in the "no symptom" class from 3% to 26.7% for bloating and from 8.4% to 44.1% for abdominal pain (P

144. Emerging from gastroesophageal reflux (Emerge): An Italian survey - II the viewpoint of the patient

Author

Bianchetti, M., Peralta, S., Nicita, R., Aragona, S. E., Ciprandi, G., Arrigoni, A., Artuso, D., Astegiano, M., Azzinnari, C., Battaglia, E., Belcari, C., Bendia, E., Benedicenti, P., Brandimarte, G., Buoncompagni, I., Cabras, M., Camilleri, S., Capece, G., Caronna, S., Cassieri, C., Castaldo, F., Catalano, T., Citarella, C., D’amore, F., D’alia, G., D’arpa, F., Dattola, A., Bortoli, N., Medici, A., Di Marzo, S., Di Mitri, R., Di Napoli, A., D’onofrio, V., Dughera, L., Elisei, W., Errico, G., Familiari, L., Familiari, P., Frasca, R., Frunzio, A., Gatti, M., Genova, S., Grosso, S., Gullotta, R., Iannuzziello, D. R., Indennitate, G., Leonardi, G., Luigiano, C., Macchiarella, B., Maisto, T., Mancino, M. G., Mancino, A., Manes, G., Marin, R., Mastinu, G. R., Moi, A., Montalbano, L. M., Monterosso, N., Morabito Loprete, A., Morlando, L., Ogliari, C., Paiano Primaldo, N., Paliani, G., Palieri, A. P., Pardocchi, D., Pati, A., Pedretti, G., Pisani, A., Plomaritis, P., Privitera, A. C., Pumpo, R., Quatraro, F., Raimondo, D., Rivellini, G., Rizzo Giovanni, L., Romano, M., Salerno, R., Edoardo Savarino, Scarpulla, G., Sinagra, E., Soncini, M., Tammaro, G., Trovato, C., Vassallo, R., Vinti, M., and Virgilio, C. M. P.

145. Efficacy of long term cyclic administration of the poorly absorbed Rifaximin in symptomatic, uncomplicted colonic diverticular disease

Author

Colecchia, A., Vestito, A., Pasqui, F., Mazzella, G., Roda, E., Pistola, F., Brandimarte, G., DAVIDE FESTI, Colecchia, Antonio, Vestito, Amanda, Pasqui, Francesca, Mazzella, Giuseppe, Roda, Enrico, Pistola, Francesca, Brandimarte, Giovanni, and Festi, Davide

Subjects
Abdominal symptom, Antibiotic, Gastroenterology, Dietary fiber, Diverticuliti
Abstract

Aim: To comparatively ate the long term efficacy of Rifaximin and dietary fibers in reducing symptoms and/or complication frequency in symptomatic, uncomplicated diverticular disease. Methods: 307 patients (118 males, 189 females, age range: 40-80 years) were enrolled in the study and randomly assigned to: Rifaximin (400 mg bid for 7 d every month) plus dietary fiber supplementation (at least 20 gr/d) or dietary fiber supplementation alone. The study duration was 24 mo; both clinical examination and symptoms' questionnaire were performed every two months. Results: Both treatments reduced symptom frequency, but Rifaximin at a greater extent, when compared to basal values. Symptomatic score declined during both treatments, but a greater reduction was evident in the Rifaximin group (6.4 ± 2.8 and 6.2 ± 2.6 at enrollment, P = NS, 1.0 ± 0.7 and 2.4 ± 1.7 after 24 mo, P < 0.001, respectively). Probability of symptom reduction was higher and complication frequency lower (Kaplan-Meyer method) in the Rifaximin group (P < 0.0001 and 0.028, respectively). Conclusion: In patients with symptomatic, uncomplicated diverticular disease, cyclic administration of Rifaximin plus dietary fiber supplementation is more effective in reducing both symptom and complication frequency than simple dietary fiber supplementation. Long term administration of the poorly absorbed antibiotic Rifaximin is safe and well tolerated by the patients, confirming the usefulness of this therapeutic strategy in the overall management of diverticular disease. © 2007 The WJG Press. All rights reserved.

148. Correlation between the reflux finding score and the gerd impact scale in patients with gastroesophageal reflux disease

Author

Bianchetti, M., Peralta, S., Nicita, R., Salvatore Emanuele Aragona, Ciprandi, G., Arrigoni, A., Artuso, D., Astegiano, M., Azzinnari, C., Battaglia, E., Belcari, C., Bendia, E., Benedicenti, P., Brandimarte, G., Buoncompagni, I., Cabras, M., Camilleri, S., Capece, G., Caronna, S., Cassieri, C., Castaldo, F., Catalano, T., Citarella, C., D’amore, F., D’alia, G., D’arpa, F., Dattola, A., Bortoli, N., Medici, A., Di Marzo, S., Di Mitri, R., Di Napoli, A., D Onofrio, V., Dughera, L., Elisei, W., Errico, G., Familiari, L., Familiari, P., Frasca, R., Frunzio, A., Gatti, M., Genova, S., Grosso, S., Gullotta, R., Iannuzziello, D. R., Indennitate, G., Leonardi, G., Luigiano, C., Macchiarella, B., Maisto, T., Mancino, M. G., Mancino, A., Manes, G., Marin, R., Mastinu, G. R., Moi, A., Montalbano, L. M., Monterosso, N., Morabito Loprete, A., Morlando, L., Ogliari, C., Paiano Primaldo, N., Paliani, G., Palieri, A. P., Pardocchi, D., Pati, A., Pedretti, G., Pisani, A., Plomaritis, P., Privitera, A. C., Pumpo, R., Quatraro, F., Raimondo, D., Rivellini, G., Rizzo Giovanni, L., Romano, M., Salerno, R., Savarino, E., Scarpulla, G., Sinagra, E., Soncini, M., Tammaro, G., Trovato, C., Vassallo, R., Vinti, M., and Virgilio, C. M. P.

149. Emerging from gastroesophageal reflux (Emerge): An Italian survey - I the viewpoint of the gastroenterologist

Author

Bianchetti, M., Peralta, S., Nicita, R., Salvatore Emanuele Aragona, Ciprandi, G., Arrigoni, A., Artuso, D., Astegiano, M., Azzinnari, C., Battaglia, E., Belcari, C., Bendia, E., Benedicenti, P., Brandimarte, G., Buoncompagni, I., Cabras, M., Camilleri, S., Capece, G., Caronna, S., Cassieri, C., Castaldo, F., Catalano, T., Citarella, C., D’amore, F., D’alia, G., D’arpa, F., Dattola, A., Bortoli, N., Medici, A., Di Marzo, S., Di Mitri, R., Di Napoli, A., D’onofrio, V., Dughera, L., Elisei, W., Errico, G., Familiari, L., Familiari, P., Frasca, R., Frunzio, A., Gatti, M., Genova, S., Grosso, S., Gullotta, R., Iannuzziello, D. R., Indennitate, G., Leonardi, G., Luigiano, C., Macchiarella, B., Maisto, T., Mancino, M. G., Mancino, A., Manes, G., Marin, R., Mastinu, G. R., Moi, A., Montalbano, L. M., Monterosso, N., Morabito Loprete, A., Morlando, L., Ogliari, C., Paiano Primaldo, N., Paliani, G., Palieri, A. P., Pardocchi, D., Pati, A., Pedretti, G., Pisani, A., Plomaritis, P., Privitera, A. C., Pumpo, R., Quatraro, F., Raimondo, D., Rivellini, G., Rizzo Giovanni, L., Romano, M., Salerno, R., Savarino, E., Scarpulla, G., Sinagra, E., Soncini, M., Tammaro, G., Trovato, C., Vassallo, R., Vinti, M., and Virgilio, C. M. P.

150. Letter: diverticulosis in inflammatory bowel diseases.

Author

Tursi, A., Elisei, W., Picchio, M., Forti, G., Giorgetti, G., Faggiani, R., Zampaletta, C., and Brandimarte, G.

Subjects
INFLAMMATORY bowel diseases, DISEASES in older people
Abstract

A letter to the editor is presented in response to the article "Systematic Review With Meta-analysis: Inflammatory Bowel Disease in the Elderly" by J. P. Gisbert in the 2014 issue.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results